Novartis India Limited (NOVARTIND.BO)
INR 789.4
(0.41%)
INR 789.4
(0.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 470.1 Million INR | -54.82% |
| 2022 | 1.04 Billion INR | -44.91% |
| 2021 | 1.88 Billion INR | -6.09% |
| 2020 | 2.01 Billion INR | -10.57% |
| 2019 | 2.24 Billion INR | -4.37% |
| 2018 | 2.35 Billion INR | -14.19% |
| 2017 | 2.74 Billion INR | -0.56% |
| 2016 | 2.75 Billion INR | -24.18% |
| 2015 | 3.63 Billion INR | -27.52% |
| 2014 | 5.01 Billion INR | 7.26% |
| 2013 | 4.67 Billion INR | 5.61% |
| 2012 | 4.42 Billion INR | 14.14% |
| 2011 | 3.87 Billion INR | 32.24% |
| 2010 | 2.93 Billion INR | 51.22% |
| 2009 | 1.93 Billion INR | 6.08% |
| 2008 | 1.82 Billion INR | 12.35% |
| 2007 | 1.62 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 45.5 Million INR | -42.84% |
| 2024 Q2 | 205.7 Million INR | 225.05% |
| 2023 Q4 | 79.6 Million INR | -58.91% |
| 2023 FY | 470.1 Million INR | -54.82% |
| 2023 Q2 | 177.8 Million INR | -19.55% |
| 2023 Q3 | 193.7 Million INR | 8.94% |
| 2023 Q1 | 221 Million INR | 150.0% |
| 2022 Q2 | 354 Million INR | 7.86% |
| 2022 Q3 | 265.1 Million INR | -25.11% |
| 2022 FY | 1.04 Billion INR | -44.91% |
| 2022 Q4 | 88.4 Million INR | -66.65% |
| 2022 Q1 | 328.2 Million INR | 20.53% |
| 2021 Q4 | 272.3 Million INR | -47.02% |
| 2021 FY | 1.88 Billion INR | -6.09% |
| 2021 Q1 | 532.6 Million INR | 49.94% |
| 2021 Q2 | 550.1 Million INR | 3.29% |
| 2021 Q3 | 514 Million INR | -6.56% |
| 2020 FY | 2.01 Billion INR | -10.57% |
| 2020 Q3 | 575.9 Million INR | 10.75% |
| 2020 Q1 | 559.9 Million INR | 86.08% |
| 2020 Q4 | 355.2 Million INR | -38.32% |
| 2020 Q2 | 520 Million INR | -7.13% |
| 2019 Q1 | 662.9 Million INR | 454.73% |
| 2019 Q4 | 300.9 Million INR | -53.31% |
| 2019 FY | 2.24 Billion INR | -4.37% |
| 2019 Q2 | 642.9 Million INR | -3.02% |
| 2019 Q3 | 644.5 Million INR | 0.25% |
| 2018 FY | 2.35 Billion INR | -14.19% |
| 2018 Q4 | 119.5 Million INR | -81.79% |
| 2018 Q3 | 656.1 Million INR | -12.58% |
| 2018 Q2 | 750.5 Million INR | -9.05% |
| 2018 Q1 | 825.2 Million INR | -9.1% |
| 2017 Q1 | 743.7 Million INR | -8.74% |
| 2017 FY | 2.74 Billion INR | -0.56% |
| 2017 Q3 | 810.5 Million INR | 0.12% |
| 2017 Q2 | 809.5 Million INR | 8.85% |
| 2017 Q4 | 907.8 Million INR | 12.0% |
| 2016 Q1 | 812.8 Million INR | -35.54% |
| 2016 Q2 | 777.4 Million INR | -4.36% |
| 2016 FY | 2.75 Billion INR | -24.18% |
| 2016 Q4 | 814.9 Million INR | 12.68% |
| 2016 Q3 | 723.2 Million INR | -6.97% |
| 2015 FY | 3.63 Billion INR | -27.52% |
| 2015 Q4 | 1.26 Billion INR | 409.7% |
| 2015 Q3 | 247.4 Million INR | 383.72% |
| 2015 Q2 | -87.2 Million INR | -108.12% |
| 2015 Q1 | 1.07 Billion INR | -42.59% |
| 2014 FY | 5.01 Billion INR | 7.26% |
| 2014 Q1 | 994.5 Million INR | -42.96% |
| 2014 Q2 | 1.15 Billion INR | 15.64% |
| 2014 Q3 | 1.22 Billion INR | 6.65% |
| 2014 Q4 | 1.87 Billion INR | 52.52% |
| 2013 Q4 | 1.74 Billion INR | 80.93% |
| 2013 FY | 4.67 Billion INR | 5.61% |
| 2013 Q3 | 963.6 Million INR | 0.47% |
| 2013 Q2 | 959.1 Million INR | -4.36% |
| 2013 Q1 | 1 Billion INR | -43.12% |
| 2012 Q4 | 1.76 Billion INR | 84.61% |
| 2012 FY | 4.42 Billion INR | 14.14% |
| 2012 Q1 | 1.15 Billion INR | -5.97% |
| 2012 Q2 | 772 Million INR | -32.89% |
| 2012 Q3 | 955 Million INR | 23.7% |
| 2011 FY | 3.87 Billion INR | 32.24% |
| 2011 Q2 | 762.3 Million INR | 0.0% |
| 2011 Q3 | 835.5 Million INR | 9.6% |
| 2011 Q4 | 1.22 Billion INR | 46.42% |
| 2010 FY | 2.93 Billion INR | 51.22% |
| 2009 FY | 1.93 Billion INR | 6.08% |
| 2008 FY | 1.82 Billion INR | 12.35% |
| 2007 FY | 1.62 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 97.038% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 98.802% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 95.962% |
| Granules India Limited | 7.18 Billion INR | 93.455% |
| Indoco Remedies Limited | 4.74 Billion INR | 90.101% |
| Achyut Healthcare Limited | 1.6 Million INR | -29116.905% |
| Ajanta Pharma Limited | 30.46 Billion INR | 98.457% |
| Alkem Laboratories Limited | 32.83 Billion INR | 98.568% |
| Alpa Laboratories Limited | 156.14 Million INR | -201.062% |
| Brooks Laboratories Limited | 51.18 Million INR | -818.523% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 81.922% |
| Bajaj HealthCare Limited | 985.34 Million INR | 52.291% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 66.876% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.51% |
| Eris Lifesciences Limited | 4.94 Billion INR | 90.489% |
| FDC Limited | 5.34 Billion INR | 91.211% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 99.304% |
| Gufic Biosciences Limited | 1.07 Billion INR | 56.38% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 77.869% |
| Ipca Laboratories Limited | 13.91 Billion INR | 96.622% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 39.217% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -918.502% |
| Lasa Supergenerics Limited | 291.17 Million INR | -61.45% |
| Laurus Labs Limited | 3.01 Billion INR | 84.386% |
| Lupin Limited | 95.67 Billion INR | 99.509% |
| Mankind Pharma Limited | 23.15 Billion INR | 97.97% |
| Medicamen Biotech Limited | 335.16 Million INR | -40.258% |
| Medico Remedies Limited | 161.84 Million INR | -190.465% |
| Megasoft Limited | 49.52 Million INR | -849.16% |
| NATCO Pharma Limited | 10.05 Billion INR | 95.326% |
| Piramal Pharma Limited | 19.91 Billion INR | 97.639% |
| RPG Life Sciences Limited | 1.63 Billion INR | 71.256% |
| Sigachi Industries Limited | 579.88 Million INR | 18.932% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.695% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 66.488% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 50.117% |
| Unichem Laboratories Limited | 6.72 Billion INR | 93.011% |
| Wanbury Limited | 1.16 Billion INR | 59.506% |
| Windlas Biotech Limited | 1 Billion INR | 53.294% |
| ZIM Laboratories Limited | 1.01 Billion INR | 53.596% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 98.911% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 84.721% |
| Divi's Laboratories Limited | 14.17 Billion INR | 96.682% |
| Hester Biosciences Limited | 908.84 Million INR | 48.275% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 84.306% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 57.224% |
| Bal Pharma Limited | 389.89 Million INR | -20.572% |
| Strides Pharma Science Limited | 9.16 Billion INR | 94.869% |
| Venus Remedies Limited | 1.91 Billion INR | 75.468% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 84.709% |
| Nectar Lifesciences Limited | 625.55 Million INR | 24.85% |
| Shilpa Medicare Limited | 2.18 Billion INR | 78.442% |
| Aarti Drugs Limited | 1.16 Billion INR | 59.734% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 57.217% |
| Suven Life Sciences Limited | 109.75 Million INR | -328.337% |
| Ind-Swift Limited | 946.56 Million INR | 50.336% |
| Valiant Laboratories Limited | 36.28 Million INR | -1195.434% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 94.415% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 89.735% |
| Themis Medicare Limited | 782.85 Million INR | 39.951% |
| Hikal Limited | 2.48 Billion INR | 81.093% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 97.806% |
| Sequent Scientific Limited | 2.9 Billion INR | 83.8% |
| Wockhardt Limited | 6.4 Billion INR | 92.655% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 96.748% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -2800.116% |
| Neuland Laboratories Limited | 2.92 Billion INR | 83.954% |
| Morepen Laboratories Limited | 1.98 Billion INR | 76.347% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -13.984% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | 30.474% |